An Update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics  by Kassamali, Zahra et al.
International Journal of Infectious Diseases 30 (2015) 125–132Review
An Update on the arsenal for multidrug-resistant Acinetobacter
infections: Polymyxin antibiotics
Zahra Kassamali a,*, Rupali Jain b,1, Larry H. Danziger c,2
aUniversity of California, Los Angeles Health System, Department of Pharmaceutical Services, 1250 16th Street Pharmaceutical Services, Room B470 Santa
Monica, CA, 90404 USA
bUniversity of Washington School of Pharmacy, Department of Pharmacy, 1959 NE Paciﬁc Street, Box 356015, EA-152 Seattle, WA 98195 USA
cUniversity of Illinois College of Pharmacy, Department of Pharmacy Practice, 833 South Wood Street, RM164, MC886, Chicago, IL 60612
A R T I C L E I N F O
Article history:
Received 4 August 2014
Received in revised form 14 October 2014
Accepted 30 October 2014
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Polymyxins/pharmacology
Polymyxins/therapeutic use
Acinetobacter infections/drug therapy
Anti-bacterial Agents/administration &
dosage
Colistin/administration & dosage
S U M M A R Y
Objective: To review recent clinical pharmacokinetic and pharmacodynamic data to optimize dosing
regimens for polymyxin B and colistin for treatment of infections due to A. baumannii.
Methods: A literature search was performed using the search terms Acinetobacter, polymyxin, colistin,
polymyxin B on MEDLINE. Additional references were identiﬁed from the resulting citations.
Results: Increasing the dose of polymyxin B or colistin and using either in combination with other
antibiotic agents demonstrates improved antimicrobial activity against Acinetobacter spp. Polymyxin B,
unlike colistin, is available as an active drug and appears to be relatively unaffected by renal function.
This is advantageous both for patients with renal impairment and for those with intact renal function.
Achieving therapeutic serum concentrations of colistin may be difﬁcult for those with intact renal
function due to rapid clearance of the prodrug, colistimethate sodium (CMS). Clinical data are still
lacking for polymyxin B, and it remains to be seen whether advantages demonstrated in PK/PD analyses
will persist in the larger scale of patient care and safety.
Conclusions: The use of higher doses of either colistin or polymyxin B, as well as combination with other
antibiotics, may prevent emerging resistance and preserve the activity of polymyxins against A. baumannii.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Acinetobacter baumannii has emerged as a signiﬁcant nosoco-
mial pathogen worldwide.1 Acinetobacter infections represented
the ninth most common nosocomial pathogen reported to the
National Healthcare Safety Network in 2006 – 2007.2 Morbidity
and mortality associated with these infections is high, with crude
mortality rates ranging from 20 - 60%.3–6 The intrinsic antimicro-
bial resistance of A. baumannii, as well as its association with
hospital and antimicrobial exposure and immunosuppressive
states, make selection of appropriate antimicrobial therapy
simultaneously more difﬁcult and more important.7
Since our review of the treatment of A. baumannii in 2004, few new
therapies have become available.1 Tigecycline, a novel tetracycline* Corresponding author. Tel.: +1 312 768 8259.
E-mail addresses: zkassamali@mednet.ucla.edu (Z. Kassamali), Rupali@uw.edu
(R. Jain), danziger@uic.edu (L.H. Danziger).
1 Tel.: +1-206-598-4416.
2 Tel.: +1-312-996-0892.
http://dx.doi.org/10.1016/j.ijid.2014.10.014
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).derivative with antibacterial activity against A. baumannii, is a notable
exception. However, FDA warnings about increased mortality
associated with the drug have led clinicians to shy away from using
it except in very limited circumstances.8 One of the most signiﬁcant
changes in the treatment of A. baumannii infections has been the
return of polymyxin antibiotics, both polymyxin B and colistin. These
antibiotics, originally developed in the 1950s, fell by the wayside due
to their toxicities and the availability of multiple other treatment
options, including a variety of beta-lactams and the ﬂuoroquino-
lones.9 Their approval, prior to current FDA new drug application
standards, has led to many questions about the appropriate use of
both colistin and polymyxin B.10 Herein we describe the use of the
polymyxins for treatment of A. baumannii infections, discuss their
overall pharmacology, and make suggestions for dosing and
combination therapy based upon recent clinical data.
2. Acinetobacter baumannii Complex
Acinetobacter spp. cause a multitude of infections, including
ventilator-associated pneumonia, line-associated bloodstreamciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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tions, and skin and soft tissue infections.2 They account for 8.4% of
all ventilator-associated pneumonia isolates, 2.2% of all nosoco-
mially-acquired central-line-associated bloodstream isolates,
1.2% of all catheter-associated urinary tract isolates, and 0.6% of
surgical site infection isolates.2 Infections due to Acinetobacter
baumannii complex represent a signiﬁcant challenge to patients
and healthcare systems given the persistence of the bacterial
organism on surfaces and its ability to rapidly develop antibacte-
rial resistance.11
With respect to use of polymyxins to treat infections due to A.
baumannii, an important characteristic of the organism is
heteroresistance. Heteroresistance, or the presence of bacteria
with mixed susceptibility patterns within a single clinical isolate, is
not detectable by standard clinical susceptibility testing meth-
ods.12,13 A. baumannii heteroresistance is particularly concerning
for neutropenic patient populations. Without an intact immune
system to prevent bacterial regrowth after initial exposure to
polymyxins, these patients may be at higher risk of developing and
harboring polymyxin-resistant A. baumannii isolates. Clinical
strategies, including novel dosing regimens and combination
antibiotic therapy, have been proposed as a solution to prevent
emerging resistance in patients treated with polymyxins for A.
baumannii infections.13–17
3. Pharmacology
Polymyxins are bactericidal drugs that exhibit their antibacte-
rial activity by disrupting bacterial cell membranes, leading to cell
lysis.9 Two commercially available polymyxin antibiotics exist:
polymyxin B and colistin (also known as polymyxin E). Colistin is
available intravenously as the prodrug, colistimethate sodium
(CMS). The availability of colistin as the prodrug CMS and the use of
two different dosing terms, milligrams of colistin base activity and
millions of international units (MU or IU) of CMS, have been the
source of signiﬁcant confusion.18–20 In this review, we will discuss
doses in terms of milligrams of colistin base activity (CBA) with
dosing in international units of CMS given in parentheses. Unlike
colistin, polymyxin B is available as the active drug. Doses in the
package insert are given in terms of international units, however a
conversion factor of 10,000 units/mg is often utilized.21,22 In this
review, polymyxin B doses will be described in terms of milligrams
with IU dosing given in parentheses, (Table 1).
3.1. Pharmacokinetics (PK) and Pharmacodynamics (PD)
For treatment of serious infections due to MDR A. baumannii,
colistin and polymyxin B are given intravenously. Neither is
bioavailable upon oral dosing, although minimal systemic
absorption has been demonstrated after CMS is administered via
inhalation. 23,24 Both polymyxin B and colistin are highly protein
bound.16,25 However, they have relatively low volumes of
distribution: 0.19 L/kg, 0.17 L/kg, and 0.4 L/kg for CMS, colistin,
and polymyxin B respectively.17,26 Each has a propensity to
accumulate in renal tissue, which likely contributes to renal
toxicity.27,28 The penetration of colistin into the cerebral spinalTable 1
Polymyxin Nomenclature
Active Drug Pro-drug Dosing Terms
Colistin (CBA) Colistimethate
sodium (CMS)
1 mg CBA = 30,000 IU CMS
Polymyxin B N/A 1 mg Polymyxin B = 10,000
IU Polymyxin B
CBA: colistin base activity, CMS: colistimethate sodium, IU: international unitsﬂuid (CSF) after intravenous dosing of CMS is only 5% of the total
colistin serum concentration.29 Higher concentrations may be
achieved using intraventricular administration.30 The penetration
of polymyxin B into CSF is not well described. However,
intraventricular administration of polymyxin B has been safely
accomplished.31
Non-renal pathways are the major route of elimination for both
colistin and polymyxin B. 25,27 The prodrug, CMS, is eliminated
renally. As result, CMS requires dose adjustment in renal
dysfunction while polymyxin B does not.16,17,32,33 In patients with
unimpaired renal function, the high rate of renal CMS elimination
raises concerns for achieving target serum concentrations.16,34 By
contrast, polymyxin B serum concentrations are not signiﬁcantly
altered by renal function, whether impaired or intact. 17,33
Metabolic pathways of drug elimination have not been described
in the literature and neither drug has demonstrated signiﬁcant
interactions with other drugs and chemicals via enzymatic
inhibition or induction.
The PK/PD parameter for both drugs involves maximizing the
ratio of drug exposure, as measured by area under the curve (AUC)
concentrations to the bacterial minimum inhibitory concentration,
(MIC).16,17,35 Target AUC:MIC values for colistin against A.
baumannii have been established in mouse thigh and lung models
and range from 17 – 95.16,35 Although established with colistin,
this information has been extrapolated to polymyxin B as well.17
These data can be used to inform patient-speciﬁc dosing regimens.
In a large pharmacokinetic study, Garonzik et al proposed
dosing equations to achieve target steady state colistin concentra-
tions.16 Based on their population PK analysis, steady state serum
concentrations of 2.5 mg/L correlated to an AUC of 60 mg*h/L.16
The authors concluded colistin dosing regimens achieving this
serum concentration would be sufﬁcient to treat an infection due
to A. baumannii with an MIC < 1 mcg/mL. Conversely, treatment of
an infection due to A. baumannii with an MIC  1 mcg/mL would
require a doubling of the dosage, raising concerns for tolerability
and toxicity.16
In 2013, Sandri et al conducted a population PK analysis of
24 patients treated with polymyxin B.17 Based upon these data,
the authors utilized Monte Carlo analysis, a simulation of a
large virtual population with varying pharmacokinetic parame-
ters, to evaluate the ability of dosing regimens to achieve a
target fAUC:MIC of 40.17 fAUC quantiﬁes the non-protein bound
concentration of polymyxin B, approximately 40% of the total
concentration, and the presumed active form of the drug.17 AUC
values varied 3-fold among virtual subjects modeled to receive
the same dose.17However, the authors concluded that a total daily
dose of 3 mg/kg/day (30,000 IU/kg/day) would be sufﬁcient
to achieve the target fAUC:MIC in subjects with infection due to
A. baumannii with an MIC  1 mcg/mL.17 Again, concerns were
raised for the ability to design a tolerable regimen to overcome
infections due to A. baumannii with an MIC > 1 mcg/mL.17
The susceptibility breakpoint for A. baumannii to colistin or
polymyxin B is 2 mcg/mL, as established by the Clinical Laboratory
Standards Institute (CLSI).36 The standard error of the test allows
for MIC variance of 1 doubling dilution.36 Therefore a reported
MIC of 1 mcg/mL may actually be anywhere between 0.5 – 2 mcg/
mL. For clinicians wishing to implement PK/PD targets in their
practice, MIC variation must be considered.10 Achieving the PK/PD
target is highly dependent upon organism MIC, given its place in
the denominator of the ratio, AUC:MIC. Susceptibility testing
assays contribute additional variation to the MIC depending on
both the method and materials used. 10,37,38 Since the correlation
of these PK/PD targets to clinical outcomes has not yet been
determined, risks must be carefully assessed for each individual
patient before signiﬁcantly increasing a dose based on an MIC
exceeding 1 mcg/mL.16,17
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The primary dose-limiting adverse effect of polymyxins is
nephrotoxicity. Neurotoxicity, ranging in severity from reversible
paresthias to respiratory failure, is a less common side effect.39
Colistin and polymyxin B are cytotoxic to renal tubular cells
which can lead to acute tubular necrosis.27,40–42 Both polymyxins
are concentrated in the kidneys via non-passive mechanisms
which are saturable.27,40–42 Nephrotoxicity is associated with
higher doses and duration of treatment.40,43,44 The mechanism
of neurotoxicity is not well-described.
Reported rates of nephrotoxicity vary widely from 0 – 55% of
patients treated with polymyxins.5,21,39,45–53 This is likely because
these data are generated from a number of small, non-comparative
studies, with heterogeneous patient populations, using different
deﬁnitions of nephrotoxicity, and varying dosing schemes.5,21,45–53
Historically, a concern for increased nephrotoxicity associated
with polymyxin B compared to colistin led to a global preference
towards the latter.40 More recent data have demonstrated
otherwise.40,43 Using validated criteria to measure acute renal
failure, two large, retrospective, comparative studies found no
differences in rate of nephrotoxicity between subjects who
received colistin or polymyxin B.40,43 In a subgroup analysis of
76 subjects matched by age, dose and duration of therapy,
comorbidities, and site of infection, acute renal toxicity was
identiﬁed in twice as many subjects who received colistin than
subjects who received polymyxin B.40
Neurotoxicities described with polymyxin therapy include
perioral paresthesias, ataxia, vertigo, visual disturbances, confu-
sion, and vasomotor instability.1,39 In rare cases, both polymyxin B
and colistin have caused neuromuscular blockade leading to
respiratory failure.39 Due to rare occurrence, limited prospective
data is available to assess neurotoxicity. In a prospective,
randomized controlled clinical trial of colistin, only 1 person
among 202 subjects reported neurotoxicity.48
5. Clinical Use
Dosing recommendations derived from PK/PD data support the
use of a loading dose in order to more rapidly achieve target serum
concentrations.16,17,34 Additionally, doses predicted to achieve
target AUC:MIC values are higher than those listed in the package
inserts for both drugs.16,17,22,54 Given the recent publications
outlining new dosing regimens, clinical data describing them
remain limited. Most information evaluating polymyxin B and
colistin for treatment of A. baumannii was collected and/or published
prior to the availability of these alternate dosing regimens. The
following discussion will review outcomes associated with the use
of colistin and polymyxin B for treatment of MDR A. baumannii
infections, bearing in mind the limitations of the doses utilized.
5.1. Monotherapy
The use of polymyxin monotherapy should only be considered
for subjects whose infections are due to carbapenem-resistant
organisms. Two studies demonstrated worse outcomes among
subjects treated with colistin or polymyxin B, primarily as
monotherapy, versus comparator antibiotics, comprised mostly
of carbapenem agents.55,56 Increased mortality identiﬁed among
subjects treated with polymyxins was likely related to differences
in baseline status; polymyxin-treated subjects tended to be
older and had greater healthcare exposure compared to subjects
who received other antibacterial agents.55,56 Nevertheless, these
data assert inappropriateness of treating patients with polymyxin
monotherapy when other treatment options, speciﬁcally the
carbapenems, are available.Three small comparative clinical studies evaluated colistin
versus imipenem or ampicillin-sulbactam for treatment of
ventilator-associated pneumonia (VAP) due to MDR A. bauman-
nii.5,45,46 In each investigation, A. baumannii infections treated
with colistin were resistant to all other routinely tested antibiotics
including penicillins, cephalosporins, carbapenems, aztreonam,
ﬂuoroquinolones, aminoglycosides, and tetracyclines.5,45,46
The largest of the three studies was a retrospective case-control
study, including 120 subjects matched by age and severity of
illness, who received colistin or imipenem.46 Remission or
resolution of symptoms occurred in approximately 75% of subjects
within both groups. In-hospital mortality occurred in 41.7% of
subjects who received colistin and 35% of those who received
imipenem; the difference was not statistically signiﬁcant.40 A
prospective comparative study of colistin versus imipenem in
35 subjects with VAP due to A. baumannii found no statistically
signiﬁcantly differences in the rates of clinical cure and mortality
across both treatment arms.5 Finally, a prospective comparison of
colistin versus ampicillin/sulbactam in 28 subjects with VAP
identiﬁed no statistically signiﬁcant differences in outcomes
between treatment groups.45 Across the three studies, rates of
clinical success ranged from 57 – 75%, and in-hospital mortality
ranged 30.3 – 61.9%.5,45,46 Although wide in range, these mortality
rates are consistent with previously published rates in patients
with VAP due to drug-resistant Gram-negative bacilli.57,58 Colistin
doses utilized in each of the studies varied from ﬁxed doses of
200 – 300 mg/day (6 – 9 MU/day) to weight-based doses of 2.5 –
3 mg/kg/day (15,000 – 75,000 IU/kg/day) without the use of a
loading dose.5,45,46 The small numbers, heterogeneous populations
and treatments included in these investigations, likely contribute
to the wide variation demonstrated among the outcomes
evaluated.5,45,46
Data evaluating polymyxin B as monotherapy for treatment of
A. baumannii are minimal. However, use of polymyxin B for
treatment of infections due to other pathogens has been
evaluated in the literature.59 One single-center, retrospective
study described outcomes in patients who received polymyxin B
monotherapy for treatment of infections due to carbapenem-
resistant K. pneumoniae (CRKP).59 Dosing varied over the 4 years
data were collected. Initially subjects received 1.5 – 2.5 mg/kg/
day (15,000 – 25,000 IU/kg/day) in divided doses. After two years,
loading doses of 2.5 mg/kg (25,000 IU/kg) were implemented.
Across all 4 years, doses were adjusted for renal dysfunction.59
Among 40 subjects, 73% improved or were cured. Thirty-day
mortality was only 18%, however 12 of the 40 subjects were
treated for a urinary tract infection. Upon univariate regression
analysis, factors associated with clinical failure included septic
shock, pneumonia, admission to the ICU, and baseline renal
dysfunction.59 After multivariate analysis, only baseline renal
dysfunction remained an independent risk factor for mortality.59
As we will discuss further, this may be related to a problem of
under-dosing as recent data suggest that polymyxin B does not
require adjustment for renal dysfunction.17,33
As demonstrated by in vitro investigations and animal models, a
principal concern with polymyxin monotherapy is bacterial
regrowth and heteroresistance.12–15 In 2 of the 3 colistin VAP
studies discussed above, failure to eradicate A. baumannii was
demonstrated in 30% of the subjects evaluated for this secondary
outcome.5,45 Repeat susceptibility testing was not reported;
therefore it is unknown whether drug resistance emerged.
Interestingly, persistence of A. baumannii is not always associated
with clinical failure.5,45 In one clinical study evaluating colistin,
failure to clear bacterial cultures was statistically signiﬁcantly
associated with clinical failure among subjects with bloodstream
infections but not among subjects with VAP.32 Among 40 subjects
treated with polymyxin B monotherapy for infection due to CRKP,
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completion of their initial antibiotic treatment. Emerging resis-
tance was detected in 6 of these subjects, 3 during their ﬁrst course
of therapy and 3 during subsequent infection.59 In spite of
treatment success, persistence of bacterial growth and emerging
resistance raises concern for long-term efﬁcacy of polymyxin
monotherapy.
5.2. Combination Therapy
Clinical, microbiological, and pharmacokinetic data for both
polymyxin B and colistin suggest important beneﬁts for use of this
class of antibiotics in combination with other antimicrobial
therapies.13,15,16,25,60 The most robust clinical antimicrobial combi-
nation therapy data for MDR A. baumannii infections have evaluated
colistin and rifampin.47–52 Collectively, these data describe out-
comes primarily for ventilator-associated and hospital-acquired
pneumonia but also include some patients with other infectious
syndromes, including bacteremia and intra-abdominal infec-
tions.47–52 Comparative studies found no statistically signiﬁcant
improvements in clinical outcomes or mortality when colistin was
combined with rifampin or given alone for the treatment of MDR A.
baumannii infections.47,48 However, combination therapy with
colistin and rifampin was associated with greater and more rapid
bacterial eradication in two prospectively designed trials.47,48
The improvement in bacterial eradication seen in these clinical
trials is consistent with animal and in vitro data demonstrating a
bactericidal beneﬁt of combination treatment.61,62 The lack of a
difference identiﬁed for clinical outcomes and mortality between
treatment arms does not preclude use of combination therapy. It is
possible that the beneﬁt of combination therapy was not detected
in a group of severely ill patients with a high propensity for
mortality based on age, organ dysfunction, cardiovascular disease,
immunocompromising conditions, and circumstances leading to
infection with MDR A. baumannii. Enrollment in the study
published by Aydemir et al achieved only half of the targeted
enrollment, thus it was likely underpowered.47 Colistin doses
employed by Durante-Mangioni et al were substantially lower
than doses that have subsequently been recommended based on
PK/PD data.16,48 Given minimal toxicity found upon the addition of
rifampin to colistin and increased rates of bacterial eradication,
there appears to be a beneﬁt associated with combination therapy.
Additional clinical data describe combination therapy with
colistin and other therapies, in particular the carbapenems.55,57
These data are retrospective in nature and demonstrate non-
statistically signiﬁcant improved rates of clinical cure and mortality
among subjects treated with colistin in combination with either
meropenem or imipenem for MDR A. baumannii infections.63,64
Two multi-center, randomized controlled trials are currently
enrolling patients to evaluate colistin monotherapy compared to
colistin and carbapenem combination therapy for the treatment
of infections due to MDR Gram-negative bacilli.65,66 Until these
data are collected and evaluated, the best combination treatment
evidence available for A. baumannii eradication supports therapy
with rifampin and colistin. Clinical circumstances, institutional
resistance rates, and individual patient characteristics, i.e. con-
comitant infections, co-morbidities, allergies, drug-drug-interac-
tions, and renal and hepatic function, should be carefully
considered when designing a combination therapy regimen.
Combination therapy data for polymyxin B are even more lacking
than for colistin.21,67,68 A 2014 observational study evaluated
104 subjects with carbapenem-resistant Gram-negative bacterial
infections.69 Subjects received polymyxin B with a loading dose of
2.5 mg/kg (25,000 IU/kg) most commonly in combination with a
carbapenem, or a carbapenem plus rifampin.69 Among 34 subjects
with A. baumannii infections, 44.1% improved or resolved their signsand symptoms, 46.8% demonstrated bacterial eradication, and 50%
survived.69 With respect to combination therapy, no statistically
signiﬁcant differences were identiﬁed; microbiological and clinical
success were more common in the subjects who received
combination therapy compared to the small group of subjects
who received polymyxin B monotherapy.69 Another single-center,
retrospective study described clinical use and outcomes among
25 patients who received polymyxin B either intravenously or
inhaled for respiratory tract infections due to MDR Gram-negative
bacilli.21 All patients received polymyxin B in combination with
another antibiotic, most commonly a carbapenem. Intravenous
polymyxin B was initiated with a loading dose of 2.5 – 3 mg/kg
(25,000 – 30,000 IU/kg) followed by 1.0 – 2.5 mg/kg/day (10,000 –
25,000 IU/kg/day) given in varying frequency based upon renal
function. Although the data were not comparative, it was noted that
bacterial eradication was associated with decreased mortality.21
Based on similar pharmacology between colistin and polymyxin B,
and in spite of minimal data evaluating combination therapy with
polymyxin B, the use of polymyxin B in combination with other
antimicrobial agents is a reasonable clinical approach to treat
infections due to MDR A. baumannii.
For treatment of infection due to MDR A. baumannii, combina-
tion antimicrobial therapy with polymyxins is associated with
greater and more rapid bacterial eradication than monother-
apy.47,48 Whether combination therapy prevents the emergence of
antimicrobial resistance clinically is not clear from the data
available. In most published clinical studies, repeat susceptibility
testing was not performed or reported.47,63,64,69 One exception is
the randomized controlled study published by Durante-Mangioni
and colleagues.48 The investigators found no incidence of emerging
resistance in A. baumannii isolates among patients assigned to
either colistin monotherapy or combination therapy treatment
arms.48 While the prevention of resistance, including hetero-
resistance, with combination therapy is well-described among in
vitro assessments, the corresponding clinical impact is not clear.
However, conventional clinical antimicrobial susceptibility meth-
ods are not designed to detect heteroresistance, which may lead to
under-reporting of this phenomenon.70 The improved microbio-
logical outcomes with combination therapy and the possibility
that bacterial persistence can lead to worse clinical outcomes
favors the use of both colistin and polymyxin B in combination
with another agent.
5.3. Inhaled Therapy
Prospective pharmacokinetic data demonstrated undetectable
colistin concentrations in the bronchoalveolar lavage (BAL) ﬂuid of
critically ill patients following intravenous administration of the
prodrug, CMS.71 Inhaled antimicrobial therapy is a strategy used to
increase drug exposure at the site of infection among patients with
bronchitis and/or pneumonia. The median peak epithelial lining
ﬂuid concentration following delivery of colistin by inhalation was
6.7 mcg/mL in a study of 20 mechanically ventilated patients.72
Concentrations of this magnitude would be expected to eradicate
infection due to colistin-susceptible A. baumannii.72 Although
there are multiple observational studies evaluating the effect of
inhaled colistin upon clinical outcomes, to date, there are no
prospective case-controlled data comparing outcomes in patients
with and without inhaled colistin. Use of inhaled colistin has been
associated with greater bacterial eradication from the lungs;
however, this has not consistently translated to differences in
clinical outcomes.73 Data regarding the use of inhaled colistin are
contradictory, with some studies demonstrating beneﬁt, and
others, a lack of beneﬁt.74,75 This may be due to heterogeneity
of patient populations and their infections, as well as the drug
delivery systems themselves. The delivery of drug particle sizes
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inhaled colistin a patient receives.72
Inhaled polymyxin B has been evaluated in one observational
study of 19 subjects with pneumonia or tracheobronchitis
primarily due to P. aeruginosa.76 Subjects received 50 mg
(500,000 IU) of inhaled polymyxin B twice daily for an average
duration of 14 days, often in combination with intravenous
antibiotics.76 While clinical improvement or cure occurred in all
but one patient, in-hospital mortality was documented in almost
half of the patients evaluated. Additionally, 4 experienced cough or
bronchospasm related to the inhaled therapy, which abated after
decreasing the dose of polymyxin B.76
Overall, the data supporting inhaled polymyxins are equivocal
as they lead to greater bacterial eradication but not always better
clinical outcomes.73 There are more data and overall experience
with inhaled colistin compared to polymyxin B. Given the high
frequency of bronchospasm or cough among the small number of
subjects evaluated for inhaled polymyxin B, the use of colistin
rather than polymyxin B is more prudent. Despite questionable
clinical efﬁcacy of inhaled colistin, the toxicity reported in both
prospective and retrospective studies is rather minimal.73,74,77 A
2007 FDA Medwatch alert reported one patient death following
administration of inhaled colistin that had been pre-mixed by the
pharmacy prior to nebulization.78 The alert concluded that pre-
mixing and storing the product in aqueous solution more than
24 hours leads to a greater rate of conversion of CMS to colistin,
and may result in toxicity to lung tissue.78 Thus, in MDR A.
baumannii pulmonary infections, this therapy may be considered
an adjunctive treatment to intravenous antibiotic therapy. Daily
doses of approximately 75 - 133 mg of CBA (approximately 1.5 -
4 MU CMS) given in 1 – 3 divided doses have been evaluated.73,77,79
6. Dosing and Dosing Strategies
Dosing recommendations for polymyxin B and colistin have
been updated signiﬁcantly in the past 3 years due to the relatively
recent availability of assays to detect concentrations of both active
and pro-drugs in serum and other biological sites.80–82 We have
selected to review this information proceeding the discussion of
polymyxin B and colistin clinically because with the exception of
one study by Dalﬁno et al, these dosing recommendations have not
yet been validated with clinical data.32
6.1. Loading Doses
In the absence of a loading dose, both polymyxin B and colistin
serum concentrations may take 2 to 3 days to achieve steady
state.17,34 Given that delaying time to appropriate antibiotic
therapy is associated with greater mortality, this provides a strong
rationale for initiating therapy with a loading dose.83Table 2
Dosing and Dose Adjustments for CMS and Polymyxin B According to Renal Function
Loading Dose Maintenance Doses
Renal Function ClCr (mL/min)  50 > 20 – 50 
CMS mg/kg CBA (MU CMS) 5 (9 MU) x1 2.5 (4.5 MU)
q 12 hours
2.5 (4.5 MU
q 24 hours
Polymyxin B mg/kg (IU/kg) 2.5 mg/kg
(25,000 IU/kg) x1
1.5 mg/kg
(15,000 IU/kg) q 12 hours
Dosing based on recommendations from Garonzik et al, Dalﬁno et al, and Sandri et al.16,17
of infection due to bacteria with an MIC  1 mcg/mL. Total body weight should be use
CBA: colistin base activity, ClCr: Creatinine clearance, CMS: colistimethate sodium, CRRT:
units
a For anuric patients, dosing targeted to achieve a steady state serum concentration
b Dose listed as total daily dose, not mg/kg.Clinical outcomes data comparing colistin dosing with and
without initial loading doses are not available. However, the PK/PD
data supporting this strategy are robust and toxicities associated
with colistin do not appear to increase with use of a loading
dose.16,17,32,69 For colistin, the safety and efﬁcacy of this strategy
was demonstrated by Dalﬁno et al, who successfully utilized
loading doses followed by maintenance therapy to treat subjects
with VAP and/or bloodstream infections.32 It should be cautioned
that safety data for polymyxin B are limited, especially for single
doses exceeding 3 mg/kg (30,000 IU/kg) or 200 mg (2,000,000 IU)
of polymyxin B per day.17,84
6.2. Dosing Weight
The colistin package insert recommends use of ideal body weight
as a dosing weight in obese patients, although data are limited with
respect to dosing in obesity.54 Gauthier et al demonstrated that
neither total daily doses nor cumulative doses of colistin were
associated with incidence of nephrotoxicity in overweight and obese
patients.85 However, the total daily doses utilized were less than
those suggested by 2011 clinical PK analyses.16,85 In the absence of
compelling data demonstrating which deﬁnition of body weight to
use, it is judicious to use ideal body weight at this time.
Polymyxin B should be dosed using total body weight in
most cases.17,33 Data regarding dosing of polymyxin B in obesity
appears to be represented in the literature by one 250 kg man with
a reported body mass index of 77.2, and renal disease, dependent
upon continuous renal replacement therapy (CRRT).17,33 The
patient received a total daily dose of 2 mg/kg (20,000 IU/kg) and
was found to have similar total drug exposure, as measured by
polymyxin B AUC, compared to a 51 kg woman also dependent
upon CRRT who received approximately 3 mg/kg/day (30,000 IU/
kg/day).33 The authors suggested dosages of polymyxin B should
be based upon actual and not ideal body weight.17 However,
caution should be exercised when selecting doses for obese
patients as drug clearance may not scale directly to body size.86
Thus, using the total body weight to calculate a dose could result in
overdose.86 Since there are minimal data to guide polymyxin B
dosing among morbidly obese patients, a prudent option is to use
an adjusted body weight.17,33,86
6.3. Dose Adjustments for Renal Dysfunction
Although renal clearance of colistin is minimal, the prodrug,
CMS, is primarily cleared via the kidneys.16 Due to the renal
dependence of CMS, the drug requires dose-adjustment for renal
dysfunction.16 Based on pharmacokinetic data published by
Garonzik et al, the initial dose of CMS should be a load, even for
patients with renal impairment (Table 2). To account for renal
dysfunction, the dosing recommendations include decreasing
the dose and/or extending the dosing interval (Table 2).16,32 20 IHDa,b CRRTa,b
) 2.5 (4.5 MU)
q 48 hours
30 mg (0.9 MU) on non-IHD days,
50 mg (1.5 MU) on IHD days, after HD
67 mg (2 MU)
q 8 hours
,32 Higher CMS doses or increased dosing frequency may be considered for treatment
d except in obese patients as discussed in the text.
 continuous renal replacement therapy, IHD: intermittent hemodialysis, MU: million
 of 1 mg/L.
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dosing recommendations are based upon achieving a serum
colistin concentration of 1 mg/L.16 Among patients dependent upon
continuous renal replacement therapy, (CRRT), a regimen of 200 mg
of CBA (6 MU CMS), divided q 8 hours, is supported by the greatest
amount of data (in a total of 9 patients).16,81,87 For intermittent
hemodialysis (IHD), the doses suggested are much lower, ranging
from 30 – 70 mg of CBA (0.9 – 2.0 MU CMS) daily. Variation in dosing
recommendations for IHD is related in part to the degree of residual
renal function remaining. This alters CMS clearance, particularly
on non-dialysis days.16 A session of hemodialysis reduces serum
concentrations of CMS and colistin substantially. This warrants use of
a supplemental dose: 30 – 50% of the daily maintenance dose,
following hemodialysis.16 Dosing equations published by Garonzik
et al utilize residual renal function as a factor to determine total
daily dose.16 In the absence of any residual renal function, their PK
analyses predict a total daily dose requirement of 30 mg of CBA
(0.9 MU of CMS) on non-dialysis days and 50 mg of CBA (1.5 MU
of CMS) on dialysis days to achieve a steady state concentration
of 1 mg/L.16 Overall, data describing clinical efﬁcacy and safety
outcomes associated with colistin dosing among patients dependent
on renal replacement therapy remain limited.
Polymyxin B is not eliminated renally.17,25,33 Only 1 - 4% of a
polymyxin B dose is excreted unchanged into the urine.17,25
Therefore, even for subjects reliant upon renal replacement
therapy, dose adjustment of polymyxin B is not required
(Table 2).17,33 Although polymyxin B is not eliminated by the
kidneys, there is still signiﬁcant renal exposure to the drug.17
About 90% of the drug ﬁltered by the glomerulus is reabsorbed by
the renal tubules.17 Therefore, patients with higher creatinine
clearance have the greatest renal tubular exposure to polymyxin B,
which may lead to greater risk of kidney injury compared to those
with lower ﬁltration rates.17
7. Conclusions
Infections due to A. baumannii continue to challenge patients,
practitioners, and healthcare systems. Given the lack of new
antibacterial agents, many clinicians have returned to the poly-
myxins. The optimal use of this class of drugs is imperative in order to
preserve their effectiveness in the face of antibacterial resistance.
Based upon PK/PD information, dosing strategies, including loading
doses, should be implemented as a means to maximize either colistin
or polymyxin B exposure without delay.16,17 Combination treatment
may also preserve the utility of polymyxin antibiotics, especially
given heteroresistance patterns of A. baumannii. The selection of an
agent to use in combination with either colistin or polymyxin B
remains a patient-speciﬁc decision in the absence of strong clinical
data supporting one agent over another. The clinical decision should
include an assessment of the site of infection, susceptibility of the
isolate, drug-drug interactions, and adverse effects.
Polymyxin B has a better PK/PD proﬁle compared to colistin,
given its availability as an active drug rather than a prodrug.25
Doses of polymyxin B appear to be relatively unaffected by renal
function, which may prove an important advantage in critically ill
patients with temporary or permanent organ dysfunction.17,33
Polymyxin B may also be useful among patients with intact renal
function, for whom achieving therapeutic serum concentrations
of colistin may be difﬁcult, due to rapid clearance of CMS.16
However, clinical data are still lacking for polymyxin B and it
remains to be seen whether advantages demonstrated in PK/PD
analyses will persist in the larger scale of patient care and safety.
Fortunately, both polymyxin B and colistin are under active
investigation. Three clinical trials are currently investigating the
use of colistin or polymyxin B as monotherapy compared to a
combination therapy with a carbapenem for treatment of resistantGram-negative bacterial infections.65,66,88 Additional studies are
evaluating polymyxin nephrotoxicity.89,90 Thus, more information
about how to optimize their use and whether one is superior to the
other will be forthcoming in the near future.
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